English
Back
Download
Log in to access Online Inquiry
Back to the Top

Note the date

$Acrivon Therapeutics (ACRV.US)$ Acrivon Therapeutics: Acr-2316, a Potential First-in-Class Dual Wee1/Pkmyt1 Inhibitor, Ind Timeline Accelerated With Filing Now Expected in Q3 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
3921 Views
Comment
Sign in to post a comment
    5273
    Followers
    23
    Following
    76K
    Visitors
    Follow